Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.50 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.48 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 3/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6849318 | 1.00 | LOXL2 (0.60) | LOXL2IDO1TAAR1SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL9116903 | 1.00 | LOXL2 (0.60) | LOXL2IDO1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL8986807 | 0.98 | LOXL2 (0.62) | LOXL2IDO1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL5264530 | 0.98 | LOXL2 (0.62) | LOXL2IDO1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL11601065 | 0.98 | LOXL2 (0.62) | LOXL2IDO1TAAR1SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL9194807 | 0.93 | ALDH1A1 (0.58) | LOXL2IDO1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL5715396 | 0.82 | LOXL2 (0.55) | LOXL2IDO1KCNJ1KCNH2MEN1 | |
| SCHEMBL16449786 | 0.82 | KMT2A (0.49) | LOXL2IDO1KCNJ1KCNH2MEN1 | |
| Hydrochloric Acid SCHEMBL1097639 | 0.81 | LOXL2 (0.55) | LOXL2IDO1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4625004 | 0.81 | LOXL2 (0.44) | LOXL2IDO1KCNJ1KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777190-B1 | Crosstalk inhibitors and their uses | BIOSITE, INC. | 2004-08-17 | — | — | US | disclosed |
| US-6380201-B1 | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| EP-0749962-B1 | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles | LILLY CO ELI (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-0579767-B1 | NOVEL CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS | BIOSITE DIAGNOSTICS INC (US) | 2000-08-23 | — | — | EP | disclosed |
| US-5962473-A | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0585310-B1 | CROSSTALK INHIBITORS AND THEIR USES | BIOSITE DIAGNOSTICS INC (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5851776-A | Conjugates and assays for simultaneous detection of multiple ligands | BIOSITE DIAGNOSTICS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5814653-A | SUMATRIPTAN FOR RELIEF OF MIGRAINE PAIN AND OTHER DISORDERS ASSOCIATED WITH PEPTIDE EXTRAVASATION DIE TO STUMULATION OF THE TRIGEMINAL GANGLIA; 5-HT 1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| EP-0832650-A2 | Use of serotonin 5-HT1F agonists for the prevention of migraine | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0824917-A2 | Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| US-5470997-A | Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0585310-A4 | CROSSTALK INHIBITORS AND THEIR USES. | BIOSITE DIAGNOSTICS INC (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0579767-A4 | NOVEL CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS. | BIOSITE DIAGNOSTICS INC (US) | 1995-05-17 | — | — | EP | disclosed |
| EP-0634999-A4 | NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS. | — | 1995-02-01 | — | — | EP | disclosed |
| EP-0634999-A1 | NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS | BIOSITE DIAGNOSTICS INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| EP-0585310-A1 | CROSSTALK INHIBITORS AND THEIR USES | BIOSITE DIAGNOSTICS INC. (US) | 1994-03-09 | — | — | EP | disclosed |
| EP-0579767-A1 | NOVEL CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS | BIOSITE DIAGNOSTICS INC. (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993020048-A1 | NOVEL AMPHETAMINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE AMPHETAMINE DERIVATIVE CONJUGATES AND LABELS | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1992018868-A1 | CROSSTALK INHIBITORS AND THEIR USES | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992018866-A1 | NOVEL CONJUGATES AND ASSAYS FOR SIMULTANEOUS DETECTION OF MULTIPLE LIGANDS | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1992-10-29 | — | — | WO | disclosed |